Apostrophe, the direct-to-consumer dermatology company that connects people directly to board-certified dermatologists, closed a seed round of $6 million led by SignalFire with participation by FJ Labs.
WHO: Co-founded by Ben Holber and Ryan Hambley, Apostrophe connects people directly to board-certified dermatologists, avoiding the doctor’s waiting room or long pharmacy line. By submitting a photo for a quick visual diagnosis from a board-certified dermatologist, your prescription will be delivered straight to your doorstep.
WHY: Apostrophe will use funds to launch custom skincare treatments, bolster their patient database, and grow a vertically integrated pharmacy.
IN THEIR OWN WORDS: “Ben, Ryan, and Chris bring an impressive consumer-centric obsession, along with deep clinical know-how to help address the access problem for dermatology,” said Wayne Hu, Partner at SignalFire. “Apostrophe’s rave reviews and its approach to efficacy speaks for itself.”
“When we started the company our vision was always to deliver more accessible and affordable dermatology care. What we didn’t expect was that physically delivering medications to our patients was the only way to guarantee they’d actually get the treatment they need,” said Ben Holber, CEO and co-founder of Apostrophe. “The retail pharmacy experience is so taxing on patients and insurance sometimes doesn’t cover their medications. Our offering removes those barriers, so anyone can get expert care and truly effective treatment.”
- Apostrophe closed a seed round of $6 million.
- The round was led by SignalFire with additional participation from FJ Labs.
- Initially, a telemedicine company that focused solely on online acne consultations, Apostrophe will begin to also offer comprehensive, custom prescription medications to treat acne, soothe rosacea, reduce wrinkles, and more.
Photo: via TechCrunch